These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19847051)

  • 1. Applications of neuroimaging to disease-modification trials in Alzheimer's disease.
    Fleisher AS; Donohue M; Chen K; Brewer JB; Aisen PS;
    Behav Neurol; 2009; 21(1):129-36. PubMed ID: 19847051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Salazar J; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 May; 13(5):561-571. PubMed ID: 27931796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention of Alzheimer's dementia: neuroimaging contributions.
    Ten Kate M; Ingala S; Schwarz AJ; Fox NC; Chételat G; van Berckel BNM; Ewers M; Foley C; Gispert JD; Hill D; Irizarry MC; Lammertsma AA; Molinuevo JL; Ritchie C; Scheltens P; Schmidt ME; Visser PJ; Waldman A; Wardlaw J; Haller S; Barkhof F
    Alzheimers Res Ther; 2018 Oct; 10(1):112. PubMed ID: 30376881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.
    Jack CR; Barnes J; Bernstein MA; Borowski BJ; Brewer J; Clegg S; Dale AM; Carmichael O; Ching C; DeCarli C; Desikan RS; Fennema-Notestine C; Fjell AM; Fletcher E; Fox NC; Gunter J; Gutman BA; Holland D; Hua X; Insel P; Kantarci K; Killiany RJ; Krueger G; Leung KK; Mackin S; Maillard P; Malone IB; Mattsson N; McEvoy L; Modat M; Mueller S; Nosheny R; Ourselin S; Schuff N; Senjem ML; Simonson A; Thompson PM; Rettmann D; Vemuri P; Walhovd K; Zhao Y; Zuk S; Weiner M
    Alzheimers Dement; 2015 Jul; 11(7):740-56. PubMed ID: 26194310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Region-of-Interest based sparse feature learning method for Alzheimer's disease identification.
    Wang L; Liu Y; Zeng X; Cheng H; Wang Z; Wang Q
    Comput Methods Programs Biomed; 2020 Apr; 187():105290. PubMed ID: 31927305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating ADNI results into Alzheimer's disease drug development programs.
    Cummings JL
    Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
    Iwatsubo T; Iwata A; Suzuki K; Ihara R; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; ; Sun CK; Beckett LA; Petersen RC; Weiner MW; Aisen PS; Donohue MC;
    Alzheimers Dement; 2018 Aug; 14(8):1077-1087. PubMed ID: 29753531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.
    Wang HF; Tan L; Cao L; Zhu XC; Jiang T; Tan MS; Liu Y; Wang C; Tsai RM; Jia JP; Yu JT;
    J Alzheimers Dis; 2016; 51(1):227-36. PubMed ID: 26836176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardization of hippocampus volumetry using automated brain structure volumetry tool for an initial Alzheimer's disease imaging biomarker.
    Abrigo J; Shi L; Luo Y; Chen Q; Chu WCW; Mok VCT;
    Acta Radiol; 2019 Jun; 60(6):769-776. PubMed ID: 30185071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Classification Algorithm by Combination of Feature Decomposition and Kernel Discriminant Analysis (KDA) for Automatic MR Brain Image Classification and AD Diagnosis.
    Elahifasaee F; Li F; Yang M
    Comput Math Methods Med; 2019; 2019():1437123. PubMed ID: 32082407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
    Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
    Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
    Lista S; Molinuevo JL; Cavedo E; Rami L; Amouyel P; Teipel SJ; Garaci F; Toschi N; Habert MO; Blennow K; Zetterberg H; O'Bryant SE; Johnson L; Galluzzi S; Bokde AL; Broich K; Herholz K; Bakardjian H; Dubois B; Jessen F; Carrillo MC; Aisen PS; Hampel H
    J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S171-91. PubMed ID: 26402088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.